Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stereotactic Radiosurgery Versus Reoperation in Small Surgically Accessible Recurrent Glioblastoma.

Neurosurgery·2026

Same author

Water-soluble fullerene derivatives mitigate cranial radiation-induced neuroinflammation and cognitive dysfunction.

Biomedical microdevices·2026

Same author

Anti-EGFR liposomal drug delivery system loaded with AGY<sub>2</sub> potentiates the anti-cancer effect of AGY<sub>2</sub> against EGFR expressed pancreatic cancer.

International journal of pharmaceutics: X·2026

Same author

Tumor radiosensitization with gold nanoparticles: evolving strategies to improve tumoral gold uptake and catalyze future clinical translation.

ACS nano medicine·2026

Same author

Novel Physical and Biological Applications of Carbon Ion Radiotherapy.

Cancers·2026

Same author

Overcoming IGF1R-Mediated Resistance to Oncolytic HSV1 and Radiotherapy via Triple Combination Therapy.

Research square·2026

Same journal

Unraveling the multifaceted roles of the aryl hydrocarbon receptor in the central nervous system: neurogenesis, neural function, and disease.

Biochemical pharmacology·2026

Same journal

4-DMB, a diclofenac derivative, alleviates DSS-induced ulcerative colitis in mice by binding TNFR1 to inhibit inflammation.

Biochemical pharmacology·2026

Same journal

Calceolarioside B alleviates airway barrier dysfunction and inflammation via targeting P2Y<sub>6</sub>R in OVA-triggered asthma.

Biochemical pharmacology·2026

Same journal

The dual-faced pyruvate kinase M2 in tumors: From cytoplasmic metabolic gatekeeper to nuclear transcriptional coactivator.

Biochemical pharmacology·2026

Same journal

A [<sup>68</sup>Ga]-labeled PDGFRβ-targeting peptide PET probe for assessing MASH-related fibrosis in diet-induced preclinical models and human liver specimens.

Biochemical pharmacology·2026

Same journal

Targeting TAK1 to overcome cisplatin resistance in lung adenocarcinoma by rewiring the NF-κB and p53 signaling.

Biochemical pharmacology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 2, 2026

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Targeting inflammatory pathways for tumor radiosensitization.

Amit Deorukhkar¹, Sunil Krishnan

¹Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Biochemical Pharmacology

|July 6, 2010

Summary

This summary is machine-generated.

Radiation resistance limits cancer treatment effectiveness. Targeting radiation-induced inflammatory pathways can enhance tumor response to radiation therapy and reduce side effects.

More Related Videos

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

Related Experiment Videos

Last Updated: Jan 2, 2026

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

Area of Science:

Oncology
Molecular Biology
Radiotherapy Research

Background:

Radiation therapy (RT) is a cornerstone cancer treatment.
Tumor resistance to RT, both inherent and acquired, impedes treatment efficacy.
Understanding inducible radiation resistance mechanisms is crucial for improving RT outcomes.

Purpose of the Study:

To elucidate the signaling pathways mediating inducible radiation resistance.
To identify druggable targets for radiosensitization.
To explore the dual role of inflammatory pathways in tumor radioresponse and normal tissue toxicity.

Main Methods:

Review of recent scientific literature on radiation signaling.
Analysis of transcription factors (TFs) like nuclear factor kappa B (NF-κB) and signal transducers and activators of transcription (STATs).
Investigation of pro-inflammatory cytokine networks (e.g., IL-1β, IL-6, TNF-α).

Main Results:

Ionizing radiation activates pro-survival pathways and key TFs (NF-κB, STATs).
Activated TFs induce genes involved in inflammation, anti-apoptosis, invasion, and angiogenesis, conferring radioresistance.
Radiation-induced inflammation contributes to treatment side effects and tumor progression.

Conclusions:

Inflammatory pathways play a critical role in modulating cancer cell response to radiation.
Targeting these pathways offers a strategy to enhance tumor radiosensitivity.
Modulating inflammation may also mitigate normal tissue side effects, widening the therapeutic window.